nodes	percent_of_prediction	percent_of_DWPC	metapath
Levofloxacin—TOP2A—Valrubicin—urinary bladder cancer	0.45	0.597	CbGbCtD
Levofloxacin—TOP2A—Epirubicin—urinary bladder cancer	0.0682	0.0903	CbGbCtD
Levofloxacin—TOP2A—Etoposide—urinary bladder cancer	0.0532	0.0704	CbGbCtD
Levofloxacin—TOP2A—Doxorubicin—urinary bladder cancer	0.0363	0.048	CbGbCtD
Levofloxacin—ABCB1—Mitomycin—urinary bladder cancer	0.0346	0.0458	CbGbCtD
Levofloxacin—SLC22A2—Cisplatin—urinary bladder cancer	0.0272	0.036	CbGbCtD
Levofloxacin—CYP3A4—Thiotepa—urinary bladder cancer	0.0157	0.0208	CbGbCtD
Levofloxacin—SLC22A6—Methotrexate—urinary bladder cancer	0.0105	0.014	CbGbCtD
Levofloxacin—ABCB1—Gemcitabine—urinary bladder cancer	0.00996	0.0132	CbGbCtD
Levofloxacin—CYP1A2—Fluorouracil—urinary bladder cancer	0.00974	0.0129	CbGbCtD
Levofloxacin—CYP1A2—Etoposide—urinary bladder cancer	0.00813	0.0108	CbGbCtD
Levofloxacin—ABCB1—Cisplatin—urinary bladder cancer	0.00724	0.00958	CbGbCtD
Levofloxacin—ABCB1—Etoposide—urinary bladder cancer	0.00711	0.00942	CbGbCtD
Levofloxacin—ABCB1—Doxorubicin—urinary bladder cancer	0.00485	0.00642	CbGbCtD
Levofloxacin—ABCB1—Methotrexate—urinary bladder cancer	0.0047	0.00622	CbGbCtD
Levofloxacin—CYP3A4—Etoposide—urinary bladder cancer	0.00426	0.00564	CbGbCtD
Levofloxacin—CYP3A4—Doxorubicin—urinary bladder cancer	0.00291	0.00385	CbGbCtD
Levofloxacin—CYP1A2—urine—urinary bladder cancer	0.00163	0.133	CbGeAlD
Levofloxacin—TOP2A—prostate gland—urinary bladder cancer	0.00122	0.0998	CbGeAlD
Levofloxacin—CYP3A4—urine—urinary bladder cancer	0.00118	0.0966	CbGeAlD
Levofloxacin—SLC22A4—prostate gland—urinary bladder cancer	0.000976	0.0799	CbGeAlD
Levofloxacin—SLC22A2—renal system—urinary bladder cancer	0.000897	0.0734	CbGeAlD
Levofloxacin—SLC22A4—seminal vesicle—urinary bladder cancer	0.000826	0.0676	CbGeAlD
Levofloxacin—SLC22A4—renal system—urinary bladder cancer	0.000665	0.0545	CbGeAlD
Levofloxacin—TOP2A—vagina—urinary bladder cancer	0.000602	0.0493	CbGeAlD
Levofloxacin—SLC22A4—female reproductive system—urinary bladder cancer	0.000533	0.0436	CbGeAlD
Levofloxacin—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000509	0.125	CbGdCrCtD
Levofloxacin—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000509	0.125	CbGdCrCtD
Levofloxacin—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000509	0.125	CbGdCrCtD
Levofloxacin—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	0.000509	0.125	CbGdCrCtD
Levofloxacin—SLC22A4—vagina—urinary bladder cancer	0.000482	0.0394	CbGeAlD
Levofloxacin—CYP1A2—renal system—urinary bladder cancer	0.000399	0.0326	CbGeAlD
Levofloxacin—TOP2A—lymph node—urinary bladder cancer	0.000389	0.0319	CbGeAlD
Levofloxacin—TOP2A—Teniposide—Etoposide—urinary bladder cancer	0.000339	0.0835	CbGdCrCtD
Levofloxacin—TOP2A—Podofilox—Etoposide—urinary bladder cancer	0.000339	0.0835	CbGdCrCtD
Levofloxacin—SLC22A4—lymph node—urinary bladder cancer	0.000312	0.0255	CbGeAlD
Levofloxacin—ABCB1—prostate gland—urinary bladder cancer	0.0003	0.0245	CbGeAlD
Levofloxacin—CYP3A4—renal system—urinary bladder cancer	0.000289	0.0236	CbGeAlD
Levofloxacin—ABCB1—seminal vesicle—urinary bladder cancer	0.000254	0.0208	CbGeAlD
Levofloxacin—CYP3A4—female reproductive system—urinary bladder cancer	0.000231	0.0189	CbGeAlD
Levofloxacin—ABCB1—epithelium—urinary bladder cancer	0.00022	0.018	CbGeAlD
Levofloxacin—ABCB1—renal system—urinary bladder cancer	0.000204	0.0167	CbGeAlD
Levofloxacin—ABCB1—urethra—urinary bladder cancer	0.000201	0.0164	CbGeAlD
Levofloxacin—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	0.000191	0.047	CbGdCrCtD
Levofloxacin—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	0.000177	0.0436	CbGdCrCtD
Levofloxacin—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	0.000177	0.0436	CbGdCrCtD
Levofloxacin—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	0.000177	0.0436	CbGdCrCtD
Levofloxacin—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000164	0.0403	CbGdCrCtD
Levofloxacin—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	0.000164	0.0403	CbGdCrCtD
Levofloxacin—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	0.000164	0.0403	CbGdCrCtD
Levofloxacin—ABCB1—female reproductive system—urinary bladder cancer	0.000164	0.0134	CbGeAlD
Levofloxacin—ABCB1—vagina—urinary bladder cancer	0.000148	0.0121	CbGeAlD
Levofloxacin—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	0.000137	0.0337	CbGdCrCtD
Levofloxacin—ABCB1—lymph node—urinary bladder cancer	9.57e-05	0.00784	CbGeAlD
Levofloxacin—TOP2A—Circadian rythm related genes—CDK4—urinary bladder cancer	8.74e-05	0.00234	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle—RRM2—urinary bladder cancer	8.73e-05	0.00234	CbGpPWpGaD
Levofloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	8.65e-05	0.00232	CbGpPWpGaD
Levofloxacin—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	8.61e-05	0.00231	CbGpPWpGaD
Levofloxacin—SLC22A4—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.59e-05	0.0023	CbGpPWpGaD
Levofloxacin—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	8.49e-05	0.00228	CbGpPWpGaD
Levofloxacin—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	8.49e-05	0.00228	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	8.3e-05	0.00223	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	8.07e-05	0.00216	CbGpPWpGaD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	7.95e-05	0.00213	CbGpPWpGaD
Levofloxacin—TOP2A—Circadian rythm related genes—PPARG—urinary bladder cancer	7.94e-05	0.00213	CbGpPWpGaD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	7.85e-05	0.0021	CbGpPWpGaD
Levofloxacin—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	7.84e-05	0.0021	CbGpPWpGaD
Levofloxacin—TOP2A—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	7.76e-05	0.00208	CbGpPWpGaD
Levofloxacin—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	7.75e-05	0.00208	CbGpPWpGaD
Levofloxacin—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	7.64e-05	0.00205	CbGpPWpGaD
Levofloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	7.51e-05	0.00201	CbGpPWpGaD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	7.44e-05	0.002	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle—SMC1A—urinary bladder cancer	7.43e-05	0.00199	CbGpPWpGaD
Levofloxacin—SLC22A2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	7.38e-05	0.00198	CbGpPWpGaD
Levofloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	7.27e-05	0.00195	CbGpPWpGaD
Levofloxacin—SLC22A6—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	7.22e-05	0.00193	CbGpPWpGaD
Levofloxacin—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	6.9e-05	0.00185	CbGpPWpGaD
Levofloxacin—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	6.68e-05	0.00179	CbGpPWpGaD
Levofloxacin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	6.68e-05	0.00179	CbGpPWpGaD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.66e-05	0.00178	CbGpPWpGaD
Levofloxacin—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	6.59e-05	0.00177	CbGpPWpGaD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	6.51e-05	0.00174	CbGpPWpGaD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	6.5e-05	0.00174	CbGpPWpGaD
Levofloxacin—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	6.23e-05	0.00167	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	6.15e-05	0.00165	CbGpPWpGaD
Levofloxacin—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	6.14e-05	0.00165	CbGpPWpGaD
Levofloxacin—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	6.12e-05	0.00164	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	6.11e-05	0.00164	CbGpPWpGaD
Levofloxacin—SLC22A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.02e-05	0.00161	CbGpPWpGaD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.88e-05	0.00158	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	5.76e-05	0.00154	CbGpPWpGaD
Levofloxacin—Sinusitis—Doxorubicin—urinary bladder cancer	5.71e-05	0.000299	CcSEcCtD
Levofloxacin—Immune system disorder—Methotrexate—urinary bladder cancer	5.7e-05	0.000298	CcSEcCtD
Levofloxacin—Dizziness—Fluorouracil—urinary bladder cancer	5.7e-05	0.000298	CcSEcCtD
Levofloxacin—Visual impairment—Epirubicin—urinary bladder cancer	5.69e-05	0.000298	CcSEcCtD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.69e-05	0.00152	CbGpPWpGaD
Levofloxacin—Mediastinal disorder—Methotrexate—urinary bladder cancer	5.69e-05	0.000297	CcSEcCtD
Levofloxacin—Agranulocytosis—Doxorubicin—urinary bladder cancer	5.68e-05	0.000297	CcSEcCtD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.68e-05	0.00152	CbGpPWpGaD
Levofloxacin—Chills—Methotrexate—urinary bladder cancer	5.66e-05	0.000296	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	5.65e-05	0.00152	CbGpPWpGaD
Levofloxacin—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	5.64e-05	0.00151	CbGpPWpGaD
Levofloxacin—Diarrhoea—Cisplatin—urinary bladder cancer	5.59e-05	0.000292	CcSEcCtD
Levofloxacin—Erythema multiforme—Epirubicin—urinary bladder cancer	5.58e-05	0.000292	CcSEcCtD
Levofloxacin—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	5.58e-05	0.0015	CbGpPWpGaD
Levofloxacin—Alopecia—Methotrexate—urinary bladder cancer	5.57e-05	0.000292	CcSEcCtD
Levofloxacin—Vomiting—Gemcitabine—urinary bladder cancer	5.57e-05	0.000291	CcSEcCtD
Levofloxacin—Bradycardia—Doxorubicin—urinary bladder cancer	5.56e-05	0.000291	CcSEcCtD
Levofloxacin—Mental disorder—Methotrexate—urinary bladder cancer	5.53e-05	0.000289	CcSEcCtD
Levofloxacin—Rash—Gemcitabine—urinary bladder cancer	5.53e-05	0.000289	CcSEcCtD
Levofloxacin—Dermatitis—Gemcitabine—urinary bladder cancer	5.52e-05	0.000289	CcSEcCtD
Levofloxacin—Eye disorder—Epirubicin—urinary bladder cancer	5.52e-05	0.000289	CcSEcCtD
Levofloxacin—Hypersensitivity—Etoposide—urinary bladder cancer	5.51e-05	0.000288	CcSEcCtD
Levofloxacin—Tinnitus—Epirubicin—urinary bladder cancer	5.5e-05	0.000288	CcSEcCtD
Levofloxacin—Malnutrition—Methotrexate—urinary bladder cancer	5.49e-05	0.000287	CcSEcCtD
Levofloxacin—Erythema—Methotrexate—urinary bladder cancer	5.49e-05	0.000287	CcSEcCtD
Levofloxacin—Haemoglobin—Doxorubicin—urinary bladder cancer	5.49e-05	0.000287	CcSEcCtD
Levofloxacin—Headache—Gemcitabine—urinary bladder cancer	5.49e-05	0.000287	CcSEcCtD
Levofloxacin—Cardiac disorder—Epirubicin—urinary bladder cancer	5.48e-05	0.000287	CcSEcCtD
Levofloxacin—Flushing—Epirubicin—urinary bladder cancer	5.48e-05	0.000287	CcSEcCtD
Levofloxacin—Vomiting—Fluorouracil—urinary bladder cancer	5.48e-05	0.000286	CcSEcCtD
Levofloxacin—Rhinitis—Doxorubicin—urinary bladder cancer	5.48e-05	0.000286	CcSEcCtD
Levofloxacin—Haemorrhage—Doxorubicin—urinary bladder cancer	5.46e-05	0.000286	CcSEcCtD
Levofloxacin—Hepatitis—Doxorubicin—urinary bladder cancer	5.46e-05	0.000286	CcSEcCtD
Levofloxacin—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	5.45e-05	0.00146	CbGpPWpGaD
Levofloxacin—Hypoaesthesia—Doxorubicin—urinary bladder cancer	5.44e-05	0.000284	CcSEcCtD
Levofloxacin—Rash—Fluorouracil—urinary bladder cancer	5.43e-05	0.000284	CcSEcCtD
Levofloxacin—Dermatitis—Fluorouracil—urinary bladder cancer	5.43e-05	0.000284	CcSEcCtD
Levofloxacin—Pharyngitis—Doxorubicin—urinary bladder cancer	5.42e-05	0.000284	CcSEcCtD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.41e-05	0.00145	CbGpPWpGaD
Levofloxacin—Headache—Fluorouracil—urinary bladder cancer	5.4e-05	0.000282	CcSEcCtD
Levofloxacin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	5.39e-05	0.000282	CcSEcCtD
Levofloxacin—Oedema peripheral—Doxorubicin—urinary bladder cancer	5.38e-05	0.000281	CcSEcCtD
Levofloxacin—Dysgeusia—Methotrexate—urinary bladder cancer	5.38e-05	0.000281	CcSEcCtD
Levofloxacin—Asthenia—Etoposide—urinary bladder cancer	5.37e-05	0.000281	CcSEcCtD
Levofloxacin—Connective tissue disorder—Doxorubicin—urinary bladder cancer	5.37e-05	0.000281	CcSEcCtD
Levofloxacin—Angiopathy—Epirubicin—urinary bladder cancer	5.36e-05	0.00028	CcSEcCtD
Levofloxacin—Urethral disorder—Doxorubicin—urinary bladder cancer	5.35e-05	0.00028	CcSEcCtD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	5.34e-05	0.00143	CbGpPWpGaD
Levofloxacin—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	5.34e-05	0.00143	CbGpPWpGaD
Levofloxacin—Immune system disorder—Epirubicin—urinary bladder cancer	5.33e-05	0.000279	CcSEcCtD
Levofloxacin—Mediastinal disorder—Epirubicin—urinary bladder cancer	5.32e-05	0.000278	CcSEcCtD
Levofloxacin—Back pain—Methotrexate—urinary bladder cancer	5.31e-05	0.000278	CcSEcCtD
Levofloxacin—Chills—Epirubicin—urinary bladder cancer	5.3e-05	0.000277	CcSEcCtD
Levofloxacin—Pruritus—Etoposide—urinary bladder cancer	5.29e-05	0.000277	CcSEcCtD
Levofloxacin—Arrhythmia—Epirubicin—urinary bladder cancer	5.27e-05	0.000276	CcSEcCtD
Levofloxacin—Visual impairment—Doxorubicin—urinary bladder cancer	5.26e-05	0.000275	CcSEcCtD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.26e-05	0.00141	CbGpPWpGaD
Levofloxacin—Alopecia—Epirubicin—urinary bladder cancer	5.22e-05	0.000273	CcSEcCtD
Levofloxacin—Nausea—Gemcitabine—urinary bladder cancer	5.21e-05	0.000272	CcSEcCtD
Levofloxacin—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	5.2e-05	0.00139	CbGpPWpGaD
Levofloxacin—Vomiting—Cisplatin—urinary bladder cancer	5.19e-05	0.000272	CcSEcCtD
Levofloxacin—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	5.18e-05	0.00139	CbGpPWpGaD
Levofloxacin—Vision blurred—Methotrexate—urinary bladder cancer	5.18e-05	0.000271	CcSEcCtD
Levofloxacin—Mental disorder—Epirubicin—urinary bladder cancer	5.17e-05	0.00027	CcSEcCtD
Levofloxacin—Erythema multiforme—Doxorubicin—urinary bladder cancer	5.17e-05	0.00027	CcSEcCtD
Levofloxacin—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	5.16e-05	0.00138	CbGpPWpGaD
Levofloxacin—Rash—Cisplatin—urinary bladder cancer	5.15e-05	0.000269	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	5.15e-05	0.00138	CbGpPWpGaD
Levofloxacin—Dermatitis—Cisplatin—urinary bladder cancer	5.15e-05	0.000269	CcSEcCtD
Levofloxacin—Erythema—Epirubicin—urinary bladder cancer	5.14e-05	0.000269	CcSEcCtD
Levofloxacin—Malnutrition—Epirubicin—urinary bladder cancer	5.14e-05	0.000269	CcSEcCtD
Levofloxacin—Diarrhoea—Etoposide—urinary bladder cancer	5.12e-05	0.000268	CcSEcCtD
Levofloxacin—Nausea—Fluorouracil—urinary bladder cancer	5.12e-05	0.000268	CcSEcCtD
Levofloxacin—Eye disorder—Doxorubicin—urinary bladder cancer	5.11e-05	0.000267	CcSEcCtD
Levofloxacin—Ill-defined disorder—Methotrexate—urinary bladder cancer	5.1e-05	0.000266	CcSEcCtD
Levofloxacin—Tinnitus—Doxorubicin—urinary bladder cancer	5.09e-05	0.000266	CcSEcCtD
Levofloxacin—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	5.09e-05	0.00136	CbGpPWpGaD
Levofloxacin—Anaemia—Methotrexate—urinary bladder cancer	5.08e-05	0.000265	CcSEcCtD
Levofloxacin—Flushing—Doxorubicin—urinary bladder cancer	5.07e-05	0.000265	CcSEcCtD
Levofloxacin—Cardiac disorder—Doxorubicin—urinary bladder cancer	5.07e-05	0.000265	CcSEcCtD
Levofloxacin—Flatulence—Epirubicin—urinary bladder cancer	5.06e-05	0.000265	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	5.06e-05	0.00136	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—GSTZ1—urinary bladder cancer	5.04e-05	0.00135	CbGpPWpGaD
Levofloxacin—Tension—Epirubicin—urinary bladder cancer	5.04e-05	0.000264	CcSEcCtD
Levofloxacin—Dysgeusia—Epirubicin—urinary bladder cancer	5.03e-05	0.000263	CcSEcCtD
Levofloxacin—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	5e-05	0.00134	CbGpPWpGaD
Levofloxacin—Nervousness—Epirubicin—urinary bladder cancer	4.99e-05	0.000261	CcSEcCtD
Levofloxacin—Back pain—Epirubicin—urinary bladder cancer	4.97e-05	0.00026	CcSEcCtD
Levofloxacin—Angiopathy—Doxorubicin—urinary bladder cancer	4.96e-05	0.000259	CcSEcCtD
Levofloxacin—Malaise—Methotrexate—urinary bladder cancer	4.95e-05	0.000259	CcSEcCtD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	4.95e-05	0.00133	CbGpPWpGaD
Levofloxacin—Dizziness—Etoposide—urinary bladder cancer	4.95e-05	0.000259	CcSEcCtD
Levofloxacin—Muscle spasms—Epirubicin—urinary bladder cancer	4.94e-05	0.000258	CcSEcCtD
Levofloxacin—Immune system disorder—Doxorubicin—urinary bladder cancer	4.93e-05	0.000258	CcSEcCtD
Levofloxacin—Vertigo—Methotrexate—urinary bladder cancer	4.93e-05	0.000258	CcSEcCtD
Levofloxacin—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.92e-05	0.000257	CcSEcCtD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	4.92e-05	0.00132	CbGpPWpGaD
Levofloxacin—Leukopenia—Methotrexate—urinary bladder cancer	4.92e-05	0.000257	CcSEcCtD
Levofloxacin—Chills—Doxorubicin—urinary bladder cancer	4.9e-05	0.000256	CcSEcCtD
Levofloxacin—Arrhythmia—Doxorubicin—urinary bladder cancer	4.88e-05	0.000255	CcSEcCtD
Levofloxacin—SLC22A6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.87e-05	0.00131	CbGpPWpGaD
Levofloxacin—Nausea—Cisplatin—urinary bladder cancer	4.85e-05	0.000254	CcSEcCtD
Levofloxacin—Vision blurred—Epirubicin—urinary bladder cancer	4.84e-05	0.000253	CcSEcCtD
Levofloxacin—Alopecia—Doxorubicin—urinary bladder cancer	4.83e-05	0.000252	CcSEcCtD
Levofloxacin—Cough—Methotrexate—urinary bladder cancer	4.79e-05	0.000251	CcSEcCtD
Levofloxacin—Mental disorder—Doxorubicin—urinary bladder cancer	4.79e-05	0.00025	CcSEcCtD
Levofloxacin—SLC22A2—Metabolism—GSTO2—urinary bladder cancer	4.78e-05	0.00128	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—NAT1—urinary bladder cancer	4.78e-05	0.00128	CbGpPWpGaD
Levofloxacin—Ill-defined disorder—Epirubicin—urinary bladder cancer	4.77e-05	0.000249	CcSEcCtD
Levofloxacin—Vomiting—Etoposide—urinary bladder cancer	4.76e-05	0.000249	CcSEcCtD
Levofloxacin—Erythema—Doxorubicin—urinary bladder cancer	4.76e-05	0.000249	CcSEcCtD
Levofloxacin—Malnutrition—Doxorubicin—urinary bladder cancer	4.76e-05	0.000249	CcSEcCtD
Levofloxacin—Anaemia—Epirubicin—urinary bladder cancer	4.75e-05	0.000248	CcSEcCtD
Levofloxacin—Agitation—Epirubicin—urinary bladder cancer	4.72e-05	0.000247	CcSEcCtD
Levofloxacin—Rash—Etoposide—urinary bladder cancer	4.72e-05	0.000247	CcSEcCtD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.72e-05	0.00126	CbGpPWpGaD
Levofloxacin—Dermatitis—Etoposide—urinary bladder cancer	4.71e-05	0.000247	CcSEcCtD
Levofloxacin—Headache—Etoposide—urinary bladder cancer	4.69e-05	0.000245	CcSEcCtD
Levofloxacin—Flatulence—Doxorubicin—urinary bladder cancer	4.69e-05	0.000245	CcSEcCtD
Levofloxacin—Chest pain—Methotrexate—urinary bladder cancer	4.68e-05	0.000245	CcSEcCtD
Levofloxacin—Arthralgia—Methotrexate—urinary bladder cancer	4.68e-05	0.000245	CcSEcCtD
Levofloxacin—Myalgia—Methotrexate—urinary bladder cancer	4.68e-05	0.000245	CcSEcCtD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	4.67e-05	0.00125	CbGpPWpGaD
Levofloxacin—Tension—Doxorubicin—urinary bladder cancer	4.67e-05	0.000244	CcSEcCtD
Levofloxacin—Dysgeusia—Doxorubicin—urinary bladder cancer	4.66e-05	0.000244	CcSEcCtD
Levofloxacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.64e-05	0.000243	CcSEcCtD
Levofloxacin—Malaise—Epirubicin—urinary bladder cancer	4.63e-05	0.000242	CcSEcCtD
Levofloxacin—Discomfort—Methotrexate—urinary bladder cancer	4.62e-05	0.000242	CcSEcCtD
Levofloxacin—Nervousness—Doxorubicin—urinary bladder cancer	4.62e-05	0.000242	CcSEcCtD
Levofloxacin—Vertigo—Epirubicin—urinary bladder cancer	4.62e-05	0.000241	CcSEcCtD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.61e-05	0.00124	CbGpPWpGaD
Levofloxacin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	4.61e-05	0.00124	CbGpPWpGaD
Levofloxacin—Syncope—Epirubicin—urinary bladder cancer	4.61e-05	0.000241	CcSEcCtD
Levofloxacin—Leukopenia—Epirubicin—urinary bladder cancer	4.6e-05	0.000241	CcSEcCtD
Levofloxacin—Back pain—Doxorubicin—urinary bladder cancer	4.6e-05	0.000241	CcSEcCtD
Levofloxacin—Muscle spasms—Doxorubicin—urinary bladder cancer	4.57e-05	0.000239	CcSEcCtD
Levofloxacin—Palpitations—Epirubicin—urinary bladder cancer	4.54e-05	0.000238	CcSEcCtD
Levofloxacin—Confusional state—Methotrexate—urinary bladder cancer	4.52e-05	0.000236	CcSEcCtD
Levofloxacin—Loss of consciousness—Epirubicin—urinary bladder cancer	4.52e-05	0.000236	CcSEcCtD
Levofloxacin—Cough—Epirubicin—urinary bladder cancer	4.48e-05	0.000235	CcSEcCtD
Levofloxacin—Anaphylactic shock—Methotrexate—urinary bladder cancer	4.48e-05	0.000234	CcSEcCtD
Levofloxacin—Vision blurred—Doxorubicin—urinary bladder cancer	4.48e-05	0.000234	CcSEcCtD
Levofloxacin—Infection—Methotrexate—urinary bladder cancer	4.45e-05	0.000233	CcSEcCtD
Levofloxacin—Nausea—Etoposide—urinary bladder cancer	4.44e-05	0.000232	CcSEcCtD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	4.44e-05	0.00119	CbGpPWpGaD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	4.44e-05	0.00119	CbGpPWpGaD
Levofloxacin—Hypertension—Epirubicin—urinary bladder cancer	4.44e-05	0.000232	CcSEcCtD
Levofloxacin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	4.41e-05	0.000231	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	4.41e-05	0.00118	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle—TERT—urinary bladder cancer	4.4e-05	0.00118	CbGpPWpGaD
Levofloxacin—Nervous system disorder—Methotrexate—urinary bladder cancer	4.4e-05	0.00023	CcSEcCtD
Levofloxacin—Anaemia—Doxorubicin—urinary bladder cancer	4.4e-05	0.00023	CcSEcCtD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.39e-05	0.00118	CbGpPWpGaD
Levofloxacin—Thrombocytopenia—Methotrexate—urinary bladder cancer	4.39e-05	0.000229	CcSEcCtD
Levofloxacin—Arthralgia—Epirubicin—urinary bladder cancer	4.38e-05	0.000229	CcSEcCtD
Levofloxacin—Myalgia—Epirubicin—urinary bladder cancer	4.38e-05	0.000229	CcSEcCtD
Levofloxacin—Chest pain—Epirubicin—urinary bladder cancer	4.38e-05	0.000229	CcSEcCtD
Levofloxacin—SLC22A2—Metabolism—UGT2B7—urinary bladder cancer	4.37e-05	0.00117	CbGpPWpGaD
Levofloxacin—Agitation—Doxorubicin—urinary bladder cancer	4.37e-05	0.000229	CcSEcCtD
Levofloxacin—Anxiety—Epirubicin—urinary bladder cancer	4.36e-05	0.000228	CcSEcCtD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.36e-05	0.00117	CbGpPWpGaD
Levofloxacin—Skin disorder—Methotrexate—urinary bladder cancer	4.35e-05	0.000228	CcSEcCtD
Levofloxacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.35e-05	0.000227	CcSEcCtD
Levofloxacin—Hyperhidrosis—Methotrexate—urinary bladder cancer	4.33e-05	0.000227	CcSEcCtD
Levofloxacin—Discomfort—Epirubicin—urinary bladder cancer	4.32e-05	0.000226	CcSEcCtD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	4.32e-05	0.00116	CbGpPWpGaD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	4.32e-05	0.00116	CbGpPWpGaD
Levofloxacin—Malaise—Doxorubicin—urinary bladder cancer	4.29e-05	0.000224	CcSEcCtD
Levofloxacin—Dry mouth—Epirubicin—urinary bladder cancer	4.28e-05	0.000224	CcSEcCtD
Levofloxacin—Vertigo—Doxorubicin—urinary bladder cancer	4.27e-05	0.000223	CcSEcCtD
Levofloxacin—Anorexia—Methotrexate—urinary bladder cancer	4.27e-05	0.000223	CcSEcCtD
Levofloxacin—Syncope—Doxorubicin—urinary bladder cancer	4.26e-05	0.000223	CcSEcCtD
Levofloxacin—Leukopenia—Doxorubicin—urinary bladder cancer	4.26e-05	0.000223	CcSEcCtD
Levofloxacin—Confusional state—Epirubicin—urinary bladder cancer	4.23e-05	0.000221	CcSEcCtD
Levofloxacin—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	4.21e-05	0.00113	CbGpPWpGaD
Levofloxacin—Palpitations—Doxorubicin—urinary bladder cancer	4.2e-05	0.00022	CcSEcCtD
Levofloxacin—Anaphylactic shock—Epirubicin—urinary bladder cancer	4.19e-05	0.000219	CcSEcCtD
Levofloxacin—Oedema—Epirubicin—urinary bladder cancer	4.19e-05	0.000219	CcSEcCtD
Levofloxacin—Hypotension—Methotrexate—urinary bladder cancer	4.19e-05	0.000219	CcSEcCtD
Levofloxacin—Loss of consciousness—Doxorubicin—urinary bladder cancer	4.18e-05	0.000219	CcSEcCtD
Levofloxacin—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	4.17e-05	0.00112	CbGpPWpGaD
Levofloxacin—Infection—Epirubicin—urinary bladder cancer	4.17e-05	0.000218	CcSEcCtD
Levofloxacin—Cough—Doxorubicin—urinary bladder cancer	4.15e-05	0.000217	CcSEcCtD
Levofloxacin—Shock—Epirubicin—urinary bladder cancer	4.13e-05	0.000216	CcSEcCtD
Levofloxacin—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	4.12e-05	0.0011	CbGpPWpGaD
Levofloxacin—Nervous system disorder—Epirubicin—urinary bladder cancer	4.11e-05	0.000215	CcSEcCtD
Levofloxacin—Thrombocytopenia—Epirubicin—urinary bladder cancer	4.11e-05	0.000215	CcSEcCtD
Levofloxacin—Hypertension—Doxorubicin—urinary bladder cancer	4.11e-05	0.000215	CcSEcCtD
Levofloxacin—Tachycardia—Epirubicin—urinary bladder cancer	4.09e-05	0.000214	CcSEcCtD
Levofloxacin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	4.08e-05	0.000214	CcSEcCtD
Levofloxacin—Skin disorder—Epirubicin—urinary bladder cancer	4.07e-05	0.000213	CcSEcCtD
Levofloxacin—SLC22A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.06e-05	0.00109	CbGpPWpGaD
Levofloxacin—Hyperhidrosis—Epirubicin—urinary bladder cancer	4.05e-05	0.000212	CcSEcCtD
Levofloxacin—Insomnia—Methotrexate—urinary bladder cancer	4.05e-05	0.000212	CcSEcCtD
Levofloxacin—Chest pain—Doxorubicin—urinary bladder cancer	4.05e-05	0.000212	CcSEcCtD
Levofloxacin—Arthralgia—Doxorubicin—urinary bladder cancer	4.05e-05	0.000212	CcSEcCtD
Levofloxacin—Myalgia—Doxorubicin—urinary bladder cancer	4.05e-05	0.000212	CcSEcCtD
Levofloxacin—Anxiety—Doxorubicin—urinary bladder cancer	4.03e-05	0.000211	CcSEcCtD
Levofloxacin—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	4.03e-05	0.00108	CbGpPWpGaD
Levofloxacin—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	4.02e-05	0.00108	CbGpPWpGaD
Levofloxacin—Paraesthesia—Methotrexate—urinary bladder cancer	4.02e-05	0.00021	CcSEcCtD
Levofloxacin—SLC22A4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.02e-05	0.00108	CbGpPWpGaD
Levofloxacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	4.02e-05	0.00021	CcSEcCtD
Levofloxacin—Discomfort—Doxorubicin—urinary bladder cancer	4e-05	0.000209	CcSEcCtD
Levofloxacin—Anorexia—Epirubicin—urinary bladder cancer	4e-05	0.000209	CcSEcCtD
Levofloxacin—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	4e-05	0.00107	CbGpPWpGaD
Levofloxacin—Dyspnoea—Methotrexate—urinary bladder cancer	4e-05	0.000209	CcSEcCtD
Levofloxacin—Somnolence—Methotrexate—urinary bladder cancer	3.98e-05	0.000208	CcSEcCtD
Levofloxacin—Dry mouth—Doxorubicin—urinary bladder cancer	3.96e-05	0.000207	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle—ATM—urinary bladder cancer	3.96e-05	0.00106	CbGpPWpGaD
Levofloxacin—Dyspepsia—Methotrexate—urinary bladder cancer	3.95e-05	0.000206	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	3.94e-05	0.00106	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—CYP4B1—urinary bladder cancer	3.94e-05	0.00106	CbGpPWpGaD
Levofloxacin—Hypotension—Epirubicin—urinary bladder cancer	3.92e-05	0.000205	CcSEcCtD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.92e-05	0.00105	CbGpPWpGaD
Levofloxacin—Confusional state—Doxorubicin—urinary bladder cancer	3.91e-05	0.000205	CcSEcCtD
Levofloxacin—Decreased appetite—Methotrexate—urinary bladder cancer	3.9e-05	0.000204	CcSEcCtD
Levofloxacin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.88e-05	0.000203	CcSEcCtD
Levofloxacin—Oedema—Doxorubicin—urinary bladder cancer	3.88e-05	0.000203	CcSEcCtD
Levofloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.87e-05	0.00104	CbGpPWpGaD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	3.87e-05	0.00104	CbGpPWpGaD
Levofloxacin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.87e-05	0.000202	CcSEcCtD
Levofloxacin—Fatigue—Methotrexate—urinary bladder cancer	3.86e-05	0.000202	CcSEcCtD
Levofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	3.86e-05	0.00103	CbGpPWpGaD
Levofloxacin—Infection—Doxorubicin—urinary bladder cancer	3.86e-05	0.000202	CcSEcCtD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	3.85e-05	0.00103	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	3.83e-05	0.00103	CbGpPWpGaD
Levofloxacin—Pain—Methotrexate—urinary bladder cancer	3.83e-05	0.0002	CcSEcCtD
Levofloxacin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.82e-05	0.0002	CcSEcCtD
Levofloxacin—Shock—Doxorubicin—urinary bladder cancer	3.82e-05	0.0002	CcSEcCtD
Levofloxacin—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.81e-05	0.000199	CcSEcCtD
Levofloxacin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.8e-05	0.000199	CcSEcCtD
Levofloxacin—Insomnia—Epirubicin—urinary bladder cancer	3.79e-05	0.000198	CcSEcCtD
Levofloxacin—Tachycardia—Doxorubicin—urinary bladder cancer	3.79e-05	0.000198	CcSEcCtD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	3.79e-05	0.00102	CbGpPWpGaD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	3.79e-05	0.00102	CbGpPWpGaD
Levofloxacin—Skin disorder—Doxorubicin—urinary bladder cancer	3.77e-05	0.000197	CcSEcCtD
Levofloxacin—Paraesthesia—Epirubicin—urinary bladder cancer	3.77e-05	0.000197	CcSEcCtD
Levofloxacin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	3.75e-05	0.000196	CcSEcCtD
Levofloxacin—Dyspnoea—Epirubicin—urinary bladder cancer	3.74e-05	0.000196	CcSEcCtD
Levofloxacin—Somnolence—Epirubicin—urinary bladder cancer	3.73e-05	0.000195	CcSEcCtD
Levofloxacin—SLC22A2—Metabolism—SLC19A1—urinary bladder cancer	3.72e-05	0.000997	CbGpPWpGaD
Levofloxacin—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	3.72e-05	0.000997	CbGpPWpGaD
Levofloxacin—Anorexia—Doxorubicin—urinary bladder cancer	3.7e-05	0.000193	CcSEcCtD
Levofloxacin—Feeling abnormal—Methotrexate—urinary bladder cancer	3.69e-05	0.000193	CcSEcCtD
Levofloxacin—Dyspepsia—Epirubicin—urinary bladder cancer	3.69e-05	0.000193	CcSEcCtD
Levofloxacin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.67e-05	0.000192	CcSEcCtD
Levofloxacin—Decreased appetite—Epirubicin—urinary bladder cancer	3.65e-05	0.000191	CcSEcCtD
Levofloxacin—Hypotension—Doxorubicin—urinary bladder cancer	3.63e-05	0.00019	CcSEcCtD
Levofloxacin—SLC22A2—Metabolism—PRSS3—urinary bladder cancer	3.62e-05	0.000971	CbGpPWpGaD
Levofloxacin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.62e-05	0.000189	CcSEcCtD
Levofloxacin—Fatigue—Epirubicin—urinary bladder cancer	3.62e-05	0.000189	CcSEcCtD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	3.61e-05	0.000967	CbGpPWpGaD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	3.61e-05	0.000967	CbGpPWpGaD
Levofloxacin—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	3.59e-05	0.000963	CbGpPWpGaD
Levofloxacin—Constipation—Epirubicin—urinary bladder cancer	3.59e-05	0.000188	CcSEcCtD
Levofloxacin—Pain—Epirubicin—urinary bladder cancer	3.59e-05	0.000188	CcSEcCtD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	3.58e-05	0.000959	CbGpPWpGaD
Levofloxacin—Urticaria—Methotrexate—urinary bladder cancer	3.56e-05	0.000186	CcSEcCtD
Levofloxacin—Abdominal pain—Methotrexate—urinary bladder cancer	3.54e-05	0.000185	CcSEcCtD
Levofloxacin—Body temperature increased—Methotrexate—urinary bladder cancer	3.54e-05	0.000185	CcSEcCtD
Levofloxacin—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.54e-05	0.000949	CbGpPWpGaD
Levofloxacin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.54e-05	0.000185	CcSEcCtD
Levofloxacin—Insomnia—Doxorubicin—urinary bladder cancer	3.51e-05	0.000184	CcSEcCtD
Levofloxacin—Paraesthesia—Doxorubicin—urinary bladder cancer	3.48e-05	0.000182	CcSEcCtD
Levofloxacin—Dyspnoea—Doxorubicin—urinary bladder cancer	3.46e-05	0.000181	CcSEcCtD
Levofloxacin—Feeling abnormal—Epirubicin—urinary bladder cancer	3.46e-05	0.000181	CcSEcCtD
Levofloxacin—Somnolence—Doxorubicin—urinary bladder cancer	3.45e-05	0.00018	CcSEcCtD
Levofloxacin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.43e-05	0.000179	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle—RB1—urinary bladder cancer	3.43e-05	0.000919	CbGpPWpGaD
Levofloxacin—Dyspepsia—Doxorubicin—urinary bladder cancer	3.42e-05	0.000179	CcSEcCtD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	3.41e-05	0.000913	CbGpPWpGaD
Levofloxacin—Decreased appetite—Doxorubicin—urinary bladder cancer	3.37e-05	0.000176	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	3.37e-05	0.000903	CbGpPWpGaD
Levofloxacin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.35e-05	0.000175	CcSEcCtD
Levofloxacin—Fatigue—Doxorubicin—urinary bladder cancer	3.35e-05	0.000175	CcSEcCtD
Levofloxacin—Urticaria—Epirubicin—urinary bladder cancer	3.33e-05	0.000174	CcSEcCtD
Levofloxacin—Pain—Doxorubicin—urinary bladder cancer	3.32e-05	0.000174	CcSEcCtD
Levofloxacin—Constipation—Doxorubicin—urinary bladder cancer	3.32e-05	0.000174	CcSEcCtD
Levofloxacin—Body temperature increased—Epirubicin—urinary bladder cancer	3.32e-05	0.000173	CcSEcCtD
Levofloxacin—Abdominal pain—Epirubicin—urinary bladder cancer	3.32e-05	0.000173	CcSEcCtD
Levofloxacin—Hypersensitivity—Methotrexate—urinary bladder cancer	3.3e-05	0.000173	CcSEcCtD
Levofloxacin—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	3.3e-05	0.000885	CbGpPWpGaD
Levofloxacin—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	3.29e-05	0.000881	CbGpPWpGaD
Levofloxacin—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.25e-05	0.000872	CbGpPWpGaD
Levofloxacin—Asthenia—Methotrexate—urinary bladder cancer	3.22e-05	0.000168	CcSEcCtD
Levofloxacin—Feeling abnormal—Doxorubicin—urinary bladder cancer	3.2e-05	0.000167	CcSEcCtD
Levofloxacin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.17e-05	0.000166	CcSEcCtD
Levofloxacin—Pruritus—Methotrexate—urinary bladder cancer	3.17e-05	0.000166	CcSEcCtD
Levofloxacin—Hypersensitivity—Epirubicin—urinary bladder cancer	3.09e-05	0.000162	CcSEcCtD
Levofloxacin—Urticaria—Doxorubicin—urinary bladder cancer	3.08e-05	0.000161	CcSEcCtD
Levofloxacin—Body temperature increased—Doxorubicin—urinary bladder cancer	3.07e-05	0.00016	CcSEcCtD
Levofloxacin—Abdominal pain—Doxorubicin—urinary bladder cancer	3.07e-05	0.00016	CcSEcCtD
Levofloxacin—Diarrhoea—Methotrexate—urinary bladder cancer	3.07e-05	0.00016	CcSEcCtD
Levofloxacin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	3.04e-05	0.000815	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	3.01e-05	0.000808	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	3.01e-05	0.000807	CbGpPWpGaD
Levofloxacin—Asthenia—Epirubicin—urinary bladder cancer	3.01e-05	0.000157	CcSEcCtD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	3e-05	0.000804	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.99e-05	0.0008	CbGpPWpGaD
Levofloxacin—Pruritus—Epirubicin—urinary bladder cancer	2.97e-05	0.000155	CcSEcCtD
Levofloxacin—Dizziness—Methotrexate—urinary bladder cancer	2.96e-05	0.000155	CcSEcCtD
Levofloxacin—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.93e-05	0.000786	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—TYMP—urinary bladder cancer	2.9e-05	0.000777	CbGpPWpGaD
Levofloxacin—Diarrhoea—Epirubicin—urinary bladder cancer	2.87e-05	0.00015	CcSEcCtD
Levofloxacin—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.86e-05	0.00015	CcSEcCtD
Levofloxacin—Vomiting—Methotrexate—urinary bladder cancer	2.85e-05	0.000149	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	2.85e-05	0.000763	CbGpPWpGaD
Levofloxacin—Rash—Methotrexate—urinary bladder cancer	2.83e-05	0.000148	CcSEcCtD
Levofloxacin—Dermatitis—Methotrexate—urinary bladder cancer	2.82e-05	0.000148	CcSEcCtD
Levofloxacin—Headache—Methotrexate—urinary bladder cancer	2.81e-05	0.000147	CcSEcCtD
Levofloxacin—Asthenia—Doxorubicin—urinary bladder cancer	2.78e-05	0.000146	CcSEcCtD
Levofloxacin—Dizziness—Epirubicin—urinary bladder cancer	2.77e-05	0.000145	CcSEcCtD
Levofloxacin—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.77e-05	0.000743	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.76e-05	0.000739	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	2.75e-05	0.000738	CbGpPWpGaD
Levofloxacin—Pruritus—Doxorubicin—urinary bladder cancer	2.75e-05	0.000144	CcSEcCtD
Levofloxacin—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.73e-05	0.000733	CbGpPWpGaD
Levofloxacin—Vomiting—Epirubicin—urinary bladder cancer	2.67e-05	0.000139	CcSEcCtD
Levofloxacin—Nausea—Methotrexate—urinary bladder cancer	2.66e-05	0.000139	CcSEcCtD
Levofloxacin—Diarrhoea—Doxorubicin—urinary bladder cancer	2.66e-05	0.000139	CcSEcCtD
Levofloxacin—Rash—Epirubicin—urinary bladder cancer	2.64e-05	0.000138	CcSEcCtD
Levofloxacin—Dermatitis—Epirubicin—urinary bladder cancer	2.64e-05	0.000138	CcSEcCtD
Levofloxacin—Headache—Epirubicin—urinary bladder cancer	2.63e-05	0.000137	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	2.62e-05	0.000702	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—NAT2—urinary bladder cancer	2.62e-05	0.000702	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.62e-05	0.000701	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.61e-05	0.0007	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.61e-05	0.0007	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.58e-05	0.000693	CbGpPWpGaD
Levofloxacin—Dizziness—Doxorubicin—urinary bladder cancer	2.57e-05	0.000134	CcSEcCtD
Levofloxacin—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.55e-05	0.000683	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	2.55e-05	0.000682	CbGpPWpGaD
Levofloxacin—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.51e-05	0.000673	CbGpPWpGaD
Levofloxacin—Nausea—Epirubicin—urinary bladder cancer	2.49e-05	0.00013	CcSEcCtD
Levofloxacin—Vomiting—Doxorubicin—urinary bladder cancer	2.47e-05	0.000129	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	2.46e-05	0.00066	CbGpPWpGaD
Levofloxacin—Rash—Doxorubicin—urinary bladder cancer	2.45e-05	0.000128	CcSEcCtD
Levofloxacin—Dermatitis—Doxorubicin—urinary bladder cancer	2.44e-05	0.000128	CcSEcCtD
Levofloxacin—Headache—Doxorubicin—urinary bladder cancer	2.43e-05	0.000127	CcSEcCtD
Levofloxacin—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	2.39e-05	0.00064	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle—EP300—urinary bladder cancer	2.34e-05	0.000628	CbGpPWpGaD
Levofloxacin—Nausea—Doxorubicin—urinary bladder cancer	2.31e-05	0.000121	CcSEcCtD
Levofloxacin—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	2.28e-05	0.000612	CbGpPWpGaD
Levofloxacin—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.28e-05	0.000612	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—RRM2—urinary bladder cancer	2.26e-05	0.000606	CbGpPWpGaD
Levofloxacin—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.22e-05	0.000595	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	2.2e-05	0.00059	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.19e-05	0.000587	CbGpPWpGaD
Levofloxacin—SLC22A2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.15e-05	0.000577	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	2.15e-05	0.000577	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.14e-05	0.000574	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—ENO2—urinary bladder cancer	2.09e-05	0.000561	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—HPGDS—urinary bladder cancer	2.09e-05	0.000561	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	2.09e-05	0.000559	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—NAT1—urinary bladder cancer	2.09e-05	0.000559	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.05e-05	0.00055	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle—MYC—urinary bladder cancer	2.04e-05	0.000547	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.03e-05	0.000545	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—GSTT1—urinary bladder cancer	2.03e-05	0.000545	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.98e-05	0.000531	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.94e-05	0.000519	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	1.91e-05	0.000511	CbGpPWpGaD
Levofloxacin—SLC22A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.9e-05	0.00051	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.87e-05	0.000502	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.87e-05	0.000501	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.78e-05	0.000478	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.73e-05	0.000465	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	1.72e-05	0.00046	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.7e-05	0.000455	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—NQO1—urinary bladder cancer	1.69e-05	0.000453	CbGpPWpGaD
Levofloxacin—TOP2A—Cell Cycle—TP53—urinary bladder cancer	1.68e-05	0.000449	CbGpPWpGaD
Levofloxacin—SLC22A2—Neuronal System—HRAS—urinary bladder cancer	1.65e-05	0.000442	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	1.62e-05	0.000435	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.61e-05	0.000431	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.61e-05	0.000431	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.58e-05	0.000424	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	1.58e-05	0.000424	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.55e-05	0.000416	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.52e-05	0.000407	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.47e-05	0.000395	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.45e-05	0.000388	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.44e-05	0.000385	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.43e-05	0.000384	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—GSTP1—urinary bladder cancer	1.41e-05	0.000377	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.33e-05	0.000355	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—TYMS—urinary bladder cancer	1.31e-05	0.000351	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—NCOR1—urinary bladder cancer	1.29e-05	0.000347	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—GSTM1—urinary bladder cancer	1.29e-05	0.000347	CbGpPWpGaD
Levofloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.28e-05	0.000342	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.27e-05	0.00034	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.26e-05	0.000339	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.25e-05	0.000335	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—GPX1—urinary bladder cancer	1.24e-05	0.000332	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.24e-05	0.000331	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.22e-05	0.000327	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—ERCC2—urinary bladder cancer	1.22e-05	0.000326	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.21e-05	0.000325	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.14e-05	0.000307	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.14e-05	0.000307	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—MTHFR—urinary bladder cancer	1.14e-05	0.000307	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.14e-05	0.000306	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.11e-05	0.000297	CbGpPWpGaD
Levofloxacin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.04e-05	0.000279	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—RRM2—urinary bladder cancer	9.86e-06	0.000264	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—TYMP—urinary bladder cancer	9.75e-06	0.000261	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—PPARG—urinary bladder cancer	9.27e-06	0.000249	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—NQO1—urinary bladder cancer	9.22e-06	0.000247	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—ENO2—urinary bladder cancer	9.13e-06	0.000245	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	9.13e-06	0.000245	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.08e-06	0.000243	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	8.91e-06	0.000239	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	8.86e-06	0.000237	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—NAT2—urinary bladder cancer	8.82e-06	0.000236	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.72e-06	0.000234	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	7.69e-06	0.000206	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—RRM2—urinary bladder cancer	7.61e-06	0.000204	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—NQO1—urinary bladder cancer	7.36e-06	0.000197	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	7.29e-06	0.000196	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—TYMS—urinary bladder cancer	7.15e-06	0.000192	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.14e-06	0.000191	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	7.07e-06	0.000189	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	7.07e-06	0.000189	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—ENO2—urinary bladder cancer	7.05e-06	0.000189	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	7.05e-06	0.000189	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.84e-06	0.000183	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—GPX1—urinary bladder cancer	6.77e-06	0.000181	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	6.65e-06	0.000178	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—PTEN—urinary bladder cancer	6.36e-06	0.000171	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	6.25e-06	0.000167	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.23e-06	0.000167	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	6.14e-06	0.000165	CbGpPWpGaD
Levofloxacin—SLC22A2—Metabolism—EP300—urinary bladder cancer	6.07e-06	0.000163	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.94e-06	0.000159	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—TYMS—urinary bladder cancer	5.71e-06	0.000153	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.68e-06	0.000152	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	5.64e-06	0.000151	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	5.64e-06	0.000151	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—GPX1—urinary bladder cancer	5.4e-06	0.000145	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	5.31e-06	0.000142	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—PPARG—urinary bladder cancer	5.07e-06	0.000136	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	4.99e-06	0.000134	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	4.87e-06	0.00013	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.74e-06	0.000127	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.41e-06	0.000118	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.36e-06	0.000117	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.36e-06	0.000117	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.17e-06	0.000112	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.09e-06	0.00011	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—PPARG—urinary bladder cancer	4.04e-06	0.000108	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.99e-06	0.000107	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	3.88e-06	0.000104	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.85e-06	0.000103	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—PTEN—urinary bladder cancer	3.48e-06	9.32e-05	CbGpPWpGaD
Levofloxacin—ABCB1—Metabolism—EP300—urinary bladder cancer	3.31e-06	8.88e-05	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	3.18e-06	8.53e-05	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.12e-06	8.37e-05	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3e-06	8.04e-05	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—PTEN—urinary bladder cancer	2.77e-06	7.44e-05	CbGpPWpGaD
Levofloxacin—CYP1A2—Metabolism—EP300—urinary bladder cancer	2.65e-06	7.09e-05	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.46e-06	6.58e-05	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.14e-06	5.74e-05	CbGpPWpGaD
Levofloxacin—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.04e-06	5.47e-05	CbGpPWpGaD
